1. Severe or life threatening respiratory disease upon admission 2. Viral pneumonia with other viruses besides COVID-19 3. Ineligible for Convalescent Plasma Therapy 4. Participation in other studies. 5. Other circumstances in which the investigator determined that the patient is not suitable for the clinical trial 6. Refusal of informed consent study participation by Donor and/or Patient 7. Known IgA deficiency 8. Medical conditions in which receipt of 220 ml volume may be detrimental to the patient (e.g.decompensated congestive heart failure) 9. Females who are pregnant or breast feeding

1. Severe or life threatening respiratory disease upon admission 2. Viral pneumonia with other viruses besides COVID-19 3. Ineligible for Convalescent Plasma Therapy 4. Participation in other studies. 5. Other circumstances in which the investigator determined that the patient is not suitable for the clinical trial 6. Refusal of informed consent study participation by Donor and/or Patient 7. Known IgA deficiency 8. Medical conditions in which receipt of 220 ml volume may be detrimental to the patient (e.g.decompensated congestive heart failure) 9. Females who are pregnant or breast feeding